Two Sigma Investments
KNTE

Two Sigma Investments’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Two Sigma Investments’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-299,633
Closed -$710K – 3479
2023
Q4 		$710K Buy
299,633
+162,163
+118% +$287K ﹤0.01% 2272
2023
Q3 		$192K Buy
137,470
+23,967
+21% +$57.6K ﹤0.01% 2648
2023
Q2 		$344K Buy
+113,503
New +$438K ﹤0.01% 2476
2022
Q4 		– Sell
-10,258
Closed -$123K – 3150
2022
Q3 		$123K Buy
+10,258
New +$134K ﹤0.01% 2199
2022
Q2 		– Sell
-22,966
Closed -$259K – 3059
2022
Q1 		$259K Buy
+22,966
New +$253K ﹤0.01% 2265
2021
Q4 		– Sell
-8,928
Closed -$206K – 5043
2021
Q3 		$206K Buy
+8,928
New +$194K ﹤0.01% 3955

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments's KNTE Position: Q1 2024 in Review

Two Sigma Investments sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2024, closing a stake of 299,633 shares — an estimated $710K sold.

Two Sigma Investments first reported a position in KNTE in Q3 2021 and held it in 6 quarters. The position peaked at $710K in Q4 2023. 56 funds tracked by Wall St. Rank hold KNTE as of Q1 2024.

  • Two Sigma Investments reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Two Sigma Investments sold 299,633 Kinnate Biopharma Inc. Common Stock shares in Q1 2024, an estimated $710K.
  • Two Sigma Investments first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2021 and held it in 6 quarters.
  • Two Sigma Investments's Kinnate Biopharma Inc. Common Stock position peaked at $710K in Q4 2023.
  • 56 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2024.

Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.